Announcement • Jul 18
AxoSim, Inc. entered into an agreement to acquire microBrain™-associated assets from Vyant Bio, Inc. (OTCPK:VYNT) for $3.5 million. AxoSim, Inc. entered into an agreement to acquire microBrain™-associated assets from Vyant Bio, Inc. (OTCPK:VYNT) for $3.5 million on July 17, 2023. The transaction calls for payments from AxoSim to Vyant Bio of $2.25 million, of which $1.1 million will be paid at close and the remainder based on milestones and the expiration of the indemnification period and release from escrow pursuant to the transaction agreement. In addition, AxoSim will assume approximately $1.2 million of future lease-related liabilities. The transaction includes microBrainTM Intellectual Property from StemoniX, Along With Expert Scientific Team and Advanced R&D and Manufacturing Facility in Minnesota. AxoSim intends to finance the acquisition and the accompanying operational expansion with participation from current and new investors.The transaction is subject to approval by Vyant Bio's shareholders. The transaction is expected to close in the next several months. LifeSci Capital, LLC acted as financial advisor to Vyant Bio. Announcement • May 17
Vyant Bio, Inc.(NasdaqCM:VYNT) dropped from S&P TMI Index Vyant Bio, Inc.(NasdaqCM:VYNT) dropped from S&P TMI Index Announcement • May 13
Vyant Bio to File a Form 15 with SEC on or About May 15 As previously announced, Vyant Bio, Inc. filed a Form 25 with the Securities and Exchange Commission (the “SEC”) on May 4, 2023 to voluntary delist its securities from The Nasdaq Capital Market (“Nasdaq”). May 12, 2023, Vyant Bio announced that, following the effectiveness of the Form 25 and the delisting of such securities from Nasdaq, which is expected on or about May 14, 2023, Vyant Bio will file a Form 15 with the SEC on or about May 15, 2023 to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and deregister such securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company expects that the deregistration of such securities will become effective 90 days after the filing of the Form 25 with the SEC. The last day of trading of the Common Stock on Nasdaq will be May 12, 2023. Following delisting of the Company’s common stock, par value $0.0001 (the “Common Stock”) from Nasdaq, the Company anticipates that the Common Stock will be quoted on the Pink Open Market operated by OTC Markets Group Inc. (the “OTC”) under the symbol “VYNT” starting on or about May 15, 2023. The Company intends to continue to provide information to its stockholders and to take such other actions within its control to enable its Common Stock to be quoted on the OTC Pink Open Market in the Pink Limited Information market tier. There is no guarantee, however, that a broker will continue to make a market in the Common Stock and that trading of the Common Stock will continue on an OTC market or otherwise. Going forward, Vyant Bio may, from time to time, when it deems appropriate, provide limited information regarding its financial status and business activities, or issue press releases for select events or developments. 
